R72.22 – R121.55 EXCL VAT
COMPOSITION: Afoxolaner 2.27% w/w.
- For the treatment and prevention of flea infestation in dogs (C. tenocephalides felis and C. canis) for at least 1 month.
- Starts killing existing fleas 30 minutes after administration; 100 % efficacy achieved by 8 hours.
- Elimination of new adult fleas on the dog within 12 hours; kills fleas before egg production and therefore prevents the risk of household contamination.
- Can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).
- For the treatment and prevention of tick infestation in dogs (Rhipicephalus sanguineus, Haemaphysalis spp.) plus various other spp.
- For optimal flea and tick control, monthly administrations are recommended.
WARNINGS: Keep out of reach of children, uninformed persons, and animals. After treatment with Nexgard, most ticks will generally be killed within 48 hours after infestation. However, the attachment of single ticks cannot be excluded and so transmission of infectious diseases cannot be completely excluded if conditions are unfavourable. Nexgard may cause vomiting and diarrhoea in some dogs. Use during pregnancy, lactation, or breeding: No data have been generated in dogs used for breeding. However, in laboratory species (rats and rabbits), afoxolaner has not produced any evidence of teratogenic effects, nor any adverse effect on the reproductive capacity in males and females. Safety in pregnant and lactating animals has not been determined. Although this remedy has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.
CONTRA-INDICATIONS: Do not use in case of hypersensitivity to the active substance or excipients.
PRECAUTIONS: In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 2kg body mass should be based on a benefit/risk assessment by the responsible veterinarian. Remove only one chewable tablet at a time from the foil-backed blister card. Administer the chewable tablet in a manner that encourages the dog to chew rather than to swallow without chewing. Care should be taken to ensure that the dog consumes the complete dose; treated animals should be observed for a few minutes after administration to ensure that part of the dose is not lost or rejected.
DOSAGE AND DIRECTIONS FOR USE: Administer orally at monthly intervals to provide the recommended dosage of 2.5mg/kg of afoxolaner per kg body mass. For dogs above 50kg, administer the appropriate combination of chewable tablets. Nexgard is recommended for use in dogs and puppies 8 weeks of age and older.
METHOD OF ADMINISTRATION: Administer the chewable tablets appropriate for your dog’s mass at monthly intervals. Because dogs find Nexgard palatable, the product can be offered to the dog by hand. Alternatively, chewable tablets can be added to a small amount of dog food, or dosed manually.
PRESENTATION: The veterinary medicinal product is individually packaged in thermoformed blisters. For each strength, the chewable tablets are available in the following pack sizes:
Small dogs (2 – 4 kg), 0.5g tablet
Medium dogs (4.1 – 10 kg) 1.25g tablet
Large dogs (10.1 – 25 kg) 3g tablet
Extra-large dogs (25.1 – 50 kg) 6g tablet
1 carton box containing one blister of 1 chewable tablet.
STORAGE: Store in a dry place, at or below 30 degrees Celcius.